MindWalk Holdings Corp., a Bio-Native AI company, announced a multi-year agreement with Teva Pharmaceuticals Australia Pty Ltd to deploy ReefIQ, MindWalk’s HYFT-powered biological context layer with specified LensAI analytical capabilities, in support of a defined scope of antibody-discovery work. Teva Australia will use the AI capabilities to support discovery decisions based on generated predictions and accelerate antibody design optimization. MindWalk has been collaborating with Teva Australia since 2018.

“We are pleased to continue our collaboration with Teva Australia through this defined deployment,” said Jennifer Bath, PhD, President and Chief Executive Officer of MindWalk.“Across the industry, the constraint in antibody discovery is no longer generating data. It is connecting and governing that data and carrying what a program team learns to the next phase. That is exactly what ReefIQ was built to do for companies.”

Under the agreement, MindWalk will provide authorized analysis of approved data sources within the agreed scope. Deployment and use will be subject to Teva Australia’s applicable information-security, privacy, data-governance, scientific-review and human-oversight requirements. Financial terms were not disclosed.

“The power of AI in drug discovery is not in generating more possibilities; it’s about helping scientists find the ones that matter. By pairing computational insight with deep biological expertise and experimental validation, we can make smarter decisions earlier and focus on antibodies with the greatest potential to become meaningful medicines,” said Anthony Doyle, Vice President, Antibody Discovery at Teva Australia.